Vaccine Asia Live: NIAID’s Effort on Dengue Vaccine R&D

Addressing Asia’s needs for vaccines in dengue, Dr Zou Lanling, Bacteriology Program Officer & Chief of Translational Sciences Section of National Institutes of Health USA, shared the efforts put into dengue vaccine R&D by National Institute of Allergy and Infectious Diseases(NIAID). NIAID conducts and supports research to develop vaccines, therapeutics and diagnostics to help understand, treat, and prevent infectious, immunologic, …

Vaccine

Vaccine Asia Live: Novel Vaccines for Emerging Diseases

Most vaccines developed target infectious diseases and cancer, with cancer vaccines being listed more under therapeutic vaccines. To enlighten us on vaccines for infectious diseases, Ms Zhang Xiaoshu, Director of Business Development at BravoBio, China, presented on the topic of Novel Vaccines for Emerging Diseases. BravoBio was founded in 2011 with its  headquarters in Shanghai and multiple sites in China. …

Round up from the World Vaccine Congress 2014

  So the World Vaccine Congress is over for its 14th year! With 80+ speakers, 40+ sponsors and over 60 sessions of scientific, corporate development and future-looking content, it was a busy few days! Opening with Dr Gregory Poland from the Mayo Clinic talking about the future of vaccinology, right from the start the focus was on what will be …

Practical application of QbD for vaccine production

What is QbD? Understanding of Product and Manufacturing Process starting with Product Development Define the desired product performance and identify critical quality attributes (CQA's) Design process to meet the requirement Continually monitor and update its manufacturing process to assure product Quality Quality is not being tested into products, rather quality is built in by design This presentation from the World …

Streamlining vaccine production with ultra-scale-down models

Interested in streamlining vaccine production with ultra-scale-down models?Why not download the full presentation to discover more about streamlining vaccine production with ultra-scale-down models : · Enabling cost-effective product quality focus in early vaccine development · Understanding the capabilities of these models; compare purification methods, gain an early insight into the operational requirements, and define the critical process requirements · Do …

China, vaccines and the WHO

News emerged this week that China is getting very close to getting one of their locally manufactured vaccines approved for aid agency use by the WHO. It will be the first vaccine achieving this status and potentially opening the doors to lucrative regional and global markets. The vaccine is against Japanese encephalitis, a debilitating mosquito-borne disease prevalent in Southeast Asia …

Plant-Based Protein Expression Coming of Age

Can plant-based protein expression systems turn into a leading industrial technology? What do you think? Tell us by commenting below. Dr John Butler-Ransohoff, Project Manager for Plant-made Pharmaceuticals, Bayer Innovations joined us at the World Vaccine Congress in Washington DC 2012 to answer this question. The advantages of plant- based expression include: speed, versatility and scalability, reduced cost of production, …

Presentation download: Developing serum-free viral vaccine production platforms and giving an edge to vaccine products

Currently leading the Animal Cell Technology Group in Bioprocessing Technology Institute at Singapore's A*STAR, Prof. Say Kong Ng joined us at World Vaccine Congress Asia last June to give a presentation on: Developing serum-free viral vaccine production platforms and giving an edge to vaccine products. He covered the following points during his presentation: Current technology for viral vaccine production Development …

Presentation download: Single use products for bioproduction: available options for cell culture and downstream processing.

Challenges facing vaccine producers include: different technology platforms make it difficult to standardize facility design and equipment; unique facility and equipment may be required for an individual vaccine or class of vaccines, and finally, many vaccines are typically low volume with high throughput products. In conclusion, there is no ‘one-size fits all' facility for all vaccine products and processes! Susan …